Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma

Proceedings of the National Academy of Sciences, Volume 123, Issue 18, May 2026. <br/>SignificanceKRAS mutations are present in the majority of pancreatic ductal adenocarcinomas (PDAC) and are key drivers of tumor progression. Although mutation-specific KRAS inhibitors (KRASi) have shown encouraging clinical activity, their therapeutic …